This is the category page. Below are all of the research programs that are associated with it
Depression:
A STUDY TO ASSESS THE LONG-TERM EFFICACY AND SAFETY OF OLANZAPINE AND FLUOXETINE COMBINATION VERSUS FLUOXETINE ONLY IN THE RELAPSE PREVENTION OF STABLIZED PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (Protocol H6P-MC-HDAY)
(1_20090602_118)
This is a multicenter randomized trial for patients with treatment-resistant depression, also known as TRD. Starting the study, each participant will receive 6-8 weeks of Olanzapine and Fluoxetine combination (OFC); and the study doctor will have the ability to adjust the dosage as needed by the participant. Participants who respond to OFC will then enter the 10-12 week open label stabilization phase; which will include dosage adjusted by the study doctor. Participants who remain stable during this time will be randomly assigned to either Fluoxetine alone or OFC. Neither the study doctor nor the participant will know what drug is being administered, only the sponsor of the study. The participants will then be followed for another 27-29 weeks or until relapse.
Inpatient Psychiatry:
CORRELATES OF CHILDHOOD TRAUMA IN HOSPITALIZED PSYCHIATRIC PATIENTS (Investigator Initiated Protocol)
(2_20090404_118)
Patients who are admitted to Lehigh Valley Hospital’s Behavioral Health Unite Two (HB-2) will be approached to participate in this study. Participants will be asked to complete five different questionnaires. The questionnaires will be anonymous. No identifiers will be collected to link the responses to any participant’s name or medical record number. The questionnaires should take approximately 30 minutes to complete.
Psychiatric Inpatients:
IMPACT OF EDUCATIONAL INTERVENTIONS IN PSYCHIATRIC PATIENTS (Investigator Initiated Protocol)
This study will take place on the inpatient behavioral health unit at LVH-Muhlenberg. Patients will be enrolled into one of two groups; the treatment group and the control group. The control group will consist of patients who agree to complete both questionnaire packets but choose not to receive educational interventions by means of the Medication Education Group. The treatment group will consist of patients who agree to complete both questionnaire packets and attend 30 or more minutes of educational intervention through the Medication Education Group. The Medication Education Group will be offered once a week on Wednesday and will be led by the Principal Investigator of this study.
